NOVN Novan Inc

Novan to Participate in H.C. Wainwright 21st Annual Global Investment Conference

Novan to Participate in H.C. Wainwright 21st Annual Global Investment Conference

MORRISVILLE, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it will participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York on Monday, September 9, 2019. Participation will include a Company presentation as well as a Q&A session. The Company will also have a number of one-on-one meetings with investors during the conference.

The Company presentation will occur on September 9, 2019 at 2:10 p.m. Eastern. The presentation will be webcast live and can be accessed through the Investors section of the Company's website at . An archived version of the webcast will be available approximately two hours following the live presentation for 7 days.

About Novan

Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases with significant unmet needs. We believe that our ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to improve patient outcomes in a variety of dermatological, women’s health and gastrointestinal diseases.

CONTACT:

(Investors & Media)

Cole Ikkala

Director, Investor Relations, Communications & Business Development

EN
03/09/2019

Underlying

NOVNNovan Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novan Inc

 PRESS RELEASE
Free
NOVN NOVAN INC

Novan Enters into Agreement to Sell Substantially All of its Assets, i...

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection – The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – A...

July 17, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockh...

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format. The Company also announced that its Chairman, President and CEO, Paula Brown Stafford, will provide a corporate update on the Company after the conclusion of the ASM, including the Company’s current focus, position...

June 5, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan Focuses Strategic Direction and Announces Restructuring

Novan Focuses Strategic Direction and Announces Restructuring – Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% – DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that following an evaluation of its commercial and developmental stage assets, it has decided to ...

May 31, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan Reports First Quarter 2023 Financial Results and Provides Corpor...

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update. The Company will host a conference call and webcast, today...

May 15, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

Novan to Report First Quarter 2023 Financial Results on May 15, 2023 DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested...

May 8, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch